Didn't Trump have anti-cannabis officials like Jeff Sessions?

Absolutely. His first-term AG, Jeff Sessions, was notoriously anti-cannabis and rescinded the protective Cole Memo. This is a major source of caution. However, advocates hope a second-term Trump, focused on legacy and economic wins, might prioritize different advisors and view the now-massive industry through a purely economic lens.

Would Trump actually support legalizing cannabis federally?

Full federal legalization is considered a long shot under any administration in the near term. The more likely scenario under Trump 2.0 is incremental reform: signing the SAFER Banking Act and not interfering with the Schedule III rescheduling process already started by the Biden administration. This would solve major business hurdles without an outright legalization endorsement.

How would rescheduling to Schedule III help cannabis businesses?

Moving cannabis from Schedule I to Schedule III would be a financial revolution for legal businesses. It would eliminate IRS code 280E, which currently prohibits them from deducting standard business expenses (rent, payroll, marketing). This would instantly improve profitability and allow companies to reinvest, leading to more stable prices and better products for consumers.

Which states would benefit most from federal policy changes?

Mature markets with oversupply, like California, Oregon, and Michigan, would benefit enormously from interstate commerce. States with strong medical or nascent adult-use programs, like Florida, Ohio, and Pennsylvania, would see accelerated investment with banking reform. Essentially, any state with a legal market stands to gain from reduced federal friction.

Trump Cannabis Industry Policy: Why Insiders Are Hopeful

The scent of political irony is thick enough to cut with a grinder. As the 2026 political season heats up, a surprising sentiment is wafting through boardrooms and grow rooms alike: a cautious, calculated optimism about the potential of a second Trump administration for the Trump cannabis industry policy landscape. This isn't about partisan alignment; it's a cold, hard bet on a dealmaker's pragmatism over ideological purity.

For an industry choked by 280E tax burdens, starved of basic banking, and trapped within state lines, the status quo is a business model killer. The hope, as whispered from Oakland to Boston, is that a Trump 2.0, unburdened by re-election concerns and staffed with business veterans, might view cannabis not as a culture war flashpoint, but as a multi-billion dollar economic engine ripe for streamlining. The devil, as always, will be in the details—or the lack thereof.

The Core of the Cautious Hope

The optimism isn't rooted in campaign promises (there are few), but in a reading of Trump's first-term actions and core political identity. The thinking goes like this: Trump is, at his heart, a deregulator and a deal-oriented businessman. The current cannabis framework is a regulatory and logistical nightmare, which to a certain mindset represents inefficiency—and an opportunity to "fix" it.

The SAFER Banking Act: A Low-Hanging Victory

This is the biggest, most immediate beacon of hope. The SAFER Banking Act, which would grant state-legal cannabis businesses access to financial services, has languished for years. It passed the House (then the SAFE Act) seven times previously. The blockade has largely been in the Senate and, potentially, a president's desk. Advocates believe a business-friendly Trump could be persuaded to sign it, seeing it as a pro-small-business and public safety measure (no more all-cash operations). It’s a tangible, bipartisan win he could claim without fully endorsing legalization.

Rescheduling: A Door Already Cracked Open

The Biden Administration's move to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act was a tectonic shift. While not full legalization, it would obliterate the crippling 280E tax code, allowing businesses to deduct standard expenses. The process is underway at the DEA and could very well be finalized during the next administration.

The bet here is twofold. First, that Trump wouldn't actively reverse a completed rescheduling, as it would be seen as a punitive move against thousands of businesses and a rejection of the FDA’s own scientific review. Second, that his appointees at the DOJ and DEA, likely focused on other priorities like border security and opioids, would simply let the bureaucratic process run its course. It’s an opportunity born of inertia rather than action.

The State's Rights Shield and Interstate Commerce

Here’s where Trump’s often-invoked "state's rights" rhetoric becomes a potential shield for the industry. The current patchwork of state laws exists because of the Cole Memo-era hands-off approach. A return to a non-interference stance for compliant state programs is the bare minimum the industry expects. The real game-changer, however, could be a push for interstate commerce. Once multiple states have mature markets (looking at you, California, Michigan, and Missouri), the pressure to allow cross-border trade of cannabis will be immense. A pragmatic administration could see the logic in federal rules for a national agricultural commodity, much like alcohol after Prohibition.

The Clear and Present Dangers

Blind optimism is for amateurs. The risks under a Trump 2.0 are stark and familiar.

* The Jeff Sessions Effect: A single antagonistic Attorney General could revive the war on drugs rhetoric and direct prosecutorial resources at the industry, creating a chilling effect even without changing the law. * Wildcard Statements: The industry thrives on stability for investment. An off-the-cuff negative comment from the Oval Office could crash valuations overnight. * Priority Shift: Cannabis could simply be ignored, leaving the essential banking and tax issues in perpetual limbo while the administration focuses elsewhere.

The industry’s strategy is to make itself too big to fail and too useful to attack. With over 440,000 full-time jobs and generating nearly $30 billion in annual sales, the economic argument is getting louder every quarter.

What This Means For You

So, you're a consumer, a home grower, or maybe just a curious observer. Why should you care about this political tea-leaf reading?

If you're a consumer, positive federal movement, however incremental, means safer, more standardized, and potentially more affordable products. Banking reform could lead to more secure transactions at your dispensary. Rescheduling would unleash a wave of R&D investment, leading to better-understood and more sophisticated products—think the difference between bathtub gin and a craft Northern Lights.

If you're an aspiring entrepreneur or investor, clarity from Washington reduces risk. It means you might finally get a loan to start that infused beverage company or secure investment for your cultivation tech. It signals that the "green rush" is maturing into a legitimate sector. Keeping an eye on trusted sources and established players like ILGM for genetics can be a smart move in a stabilizing market.

For everyone, it moves the needle toward normalization. It’s a step away from the shadows and a step toward a future where cannabis is regulated like the agricultural product it is, not feared as a Schedule I bogeyman. The path isn't guaranteed, and there will be twists, but the industry is no longer just hoping for the best—it’s preparing to negotiate for it.

Weed Industry's Cautious Optimism for Trump 2.0